About AInnovia

We are pioneering the future of autoimmune disease detection through Machine Learning

Early, accurate diagnosis accessible to everyone, everywhere

Our Mission

To democratize access to Machine Learning-powered autoimmune disease diagnostic tools across the globe, enabling early detection that saves lives and improves patient outcomes.

Autoimmune diseases affect 1 in 10 people worldwide and have become significantly more prevalent after COVID-19. Yet, healthcare channels for these diseases are not available in semi-urban and rural areas, creating a critical gap in healthcare access.

Our Vision

A world where autoimmune diseases are detected early and accurately, regardless of geographic location or economic status, through the power of Machine Learning.

1 in 10
People Affected
3rd
Most Common Disease
95%
Model Accuracy
30s
Diagnosis Time

Our Core Values

These values guide everything we do, from product development to patient care.

Patient-Centric

Every decision we make is guided by our commitment to improving patient outcomes and saving lives through early detection.

Innovation

We continuously push the boundaries of AI and medical technology to create breakthrough solutions for healthcare challenges.

Accuracy

We maintain the highest standards of diagnostic accuracy, ensuring reliable results that healthcare professionals can trust.

Accessibility

We believe healthcare should be accessible to everyone, regardless of geographic location or economic status.

Our Journey

From inception to market-ready solution, here's how we're revolutionizing autoimmune disease detection.

2023

Company Formation

AInnovia was founded with a mission to democratize autoimmune disease detection

2024

Product Prototype

Developed ML-powered prototype achieving 95% concordance with expert pathologists

2024

Data Banking

Built comprehensive ANA-IFA image database with expert annotations

2025

Market Ready

Preparing for regulatory approval and commercial deployment